Literature DB >> 18975050

Ductal carcinoma in situ: correlation between FDG-PET/CT and histopathology.

Asako Azuma1, Mitsuhiro Tozaki, Kensuke Ito, Eisuke Fukuma, Tomoko Tanaka, Toshihiro O'uchi.   

Abstract

PURPOSE: The aim of this study was to determine if any correlation exists between tumor cell density and fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET)/CT) for pure or predominant ductal carcinoma in situ (DCIS).
MATERIALS AND METHODS: Subjects in this retrospective review comprised 11 patients who underwent FDG-PET/CT for DCIS. Pathological tumor cell density and FDG-PET/CT images were compared. A tumor background count density ratio of >1.5 was defined as the detectable range for DCIS.
RESULTS: Pathological density of disease was high in eight patients, intermediate in one, and low in two. In all eight patients with a detectable intraductal component on PET/CT, the density of disease was classified as high. In three patients undetected by PET/CT, the density of disease was classified as intermediate or low. On statistical analysis, the correlation between the density of disease and tumor background count density ratio (TBCDR) on PET/CT was significant (<0.05), whereas the nuclear grade and Van Nuys grade were not significant. In the eight patients detected by PET/CT, the discrepancy between histopathological mapping and FDG-PET/CT mapping was >20 mm in four patients and represented underestimation in four patients who showed low density of disease in the peripheral area.
CONCLUSIONS: Tumor cell density of intraductal carcinoma appears strongly correlated to detection by FDG-PET/CT.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18975050     DOI: 10.1007/s11604-008-0263-6

Source DB:  PubMed          Journal:  Radiat Med        ISSN: 0288-2043


  12 in total

1.  Application of the van nuys prognostic index in a retrospective series of 367 ductal carcinomas in situ of the breast examined by serial macroscopic sectioning: practical considerations.

Authors:  I de Mascarel; F Bonichon; G MacGrogan; C T de Lara; A Avril; V Picot; M Durand; L Mauriac; M Trojani; J M Coindre
Journal:  Breast Cancer Res Treat       Date:  2000-05       Impact factor: 4.872

2.  Positron emission tomography in breast cancer: a clinicopathological correlation of results.

Authors:  A Y Rostom; J Powe; A Kandil; A Ezzat; S Bakheet; F el-Khwsky; G el-Hussainy; R Sorbris; O Sjoklint
Journal:  Br J Radiol       Date:  1999-11       Impact factor: 3.039

3.  Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose.

Authors:  N Avril; J Dose; F Jänicke; S Bense; S Ziegler; C Laubenbacher; W Römer; H Pache; M Herz; B Allgayer; W Nathrath; H Graeff; M Schwaiger
Journal:  J Clin Oncol       Date:  1996-06       Impact factor: 44.544

4.  Standardized uptake values of normal breast tissue with 2-deoxy-2-[F-18]fluoro-D: -glucose positron emission tomography: variations with age, breast density, and menopausal status.

Authors:  Rakesh Kumar; Anil Chauhan; Hongming Zhuang; Prem Chandra; Mitchell Schnall; Abass Alavi
Journal:  Mol Imaging Biol       Date:  2006 Nov-Dec       Impact factor: 3.488

5.  3D-MR mammography-guided breast conserving surgery after neoadjuvant chemotherapy: clinical results and future perspectives with reference to FDG-PET.

Authors:  S Nakamura; H Kenjo; T Nishio; T Kazama; O Do; K Suzuki
Journal:  Breast Cancer       Date:  2001       Impact factor: 4.239

6.  Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis.

Authors:  N Avril; M Menzel; J Dose; M Schelling; W Weber; F Jänicke; W Nathrath; M Schwaiger
Journal:  J Nucl Med       Date:  2001-01       Impact factor: 10.057

7.  Dual time point 18F-FDG PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes.

Authors:  Ayse Mavi; Muammer Urhan; Jian Q Yu; Hongming Zhuang; Mohamed Houseni; Tevfik F Cermik; Dhurairaj Thiruvenkatasamy; Brian Czerniecki; Mitchell Schnall; Abass Alavi
Journal:  J Nucl Med       Date:  2006-09       Impact factor: 10.057

8.  Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations.

Authors:  N Avril; C A Rosé; M Schelling; J Dose; W Kuhn; S Bense; W Weber; S Ziegler; H Graeff; M Schwaiger
Journal:  J Clin Oncol       Date:  2000-10-15       Impact factor: 44.544

9.  FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters.

Authors:  Andreas Buck; Holger Schirrmeister; Thorsten Kühn; Changxian Shen; Thomas Kalker; Jörg Kotzerke; Anja Dankerl; Gerhard Glatting; Sven Reske; Torsten Mattfeldt
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-07-26       Impact factor: 9.236

10.  Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays.

Authors:  F Dehdashti; J E Mortimer; B A Siegel; L K Griffeth; T J Bonasera; M J Fusselman; D D Detert; P D Cutler; J A Katzenellenbogen; M J Welch
Journal:  J Nucl Med       Date:  1995-10       Impact factor: 10.057

View more
  5 in total

1.  Can dedicated breast PET help to reduce overdiagnosis and overtreatment by differentiating between indolent and potentially aggressive ductal carcinoma in situ?

Authors:  Lucía Graña-López; Michel Herranz; Inés Domínguez-Prado; Sonia Argibay; Ángeles Villares; Manuel Vázquez-Caruncho
Journal:  Eur Radiol       Date:  2019-08-02       Impact factor: 5.315

2.  Impact of consensus contours from multiple PET segmentation methods on the accuracy of functional volume delineation.

Authors:  A Schaefer; M Vermandel; C Baillet; A S Dewalle-Vignion; R Modzelewski; P Vera; L Massoptier; C Parcq; D Gibon; T Fechter; U Nemer; I Gardin; U Nestle
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-11-14       Impact factor: 9.236

3.  18F-fluorodeoxyglucose uptake as predictor for invasion in preoperatively diagnosed breast ductal carcinoma in situ: Significance in cases without mass formation.

Authors:  Takaaki Fujii; Reina Yajima; Hironori Tatsuki; Hiroyuki Kuwano
Journal:  Mol Clin Oncol       Date:  2017-06-29

4.  Cytochrome c1 in ductal carcinoma in situ of breast associated with proliferation and comedo necrosis.

Authors:  Mayuko Chishiki; Kiyoshi Takagi; Ai Sato; Yasuhiro Miki; Yuta Yamamoto; Akiko Ebata; Yukiko Shibahara; Mika Watanabe; Takanori Ishida; Hironobu Sasano; Takashi Suzuki
Journal:  Cancer Sci       Date:  2017-05-19       Impact factor: 6.716

5.  Is there a difference in FDG PET findings of invasive ductal carcinoma of the breast with and without coexisting DCIS?

Authors:  Ismet Sarikaya; Ali Sarikaya; Ahmed N Albatineh; Ebru Tastekin; Yavuz Atakan Sezer
Journal:  Asia Ocean J Nucl Med Biol       Date:  2020
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.